Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
View Patent ↗The present invention is directed to novel tricyclic heterocycles of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
1. A compound of structural formula I:
or a pharmaceutically acceptable salts thereof; wherein
R 1 is selected from the group consisting of C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl, benzyl, heterocycle and C 1 -C 6 alkylheterocycle; wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl, benzyl, heterocycle and C 1 -C 6 alkylheterocycle are unsubstituted or substituted with 1-3 substituents each independently selected from R 5 ;
R 2 , R 3 and R 4 are independently selected from the group consisting of hydrogen and C 1 -C 6 alkyl wherein the C 1 -C 6 alkyl is unsubstituted or substituted with one or more substituents selected from R 5 ; and
R 5 is selected from the group consisting of hydrogen, halogen, C 1 -C 6 alkyl, halogen-substitutedC 1 -C 6 alkyl, —OH, C 1 -C 6 alkylOH, halogen-substitutedC 1 -C 6 alkylOH, —OC 1 -C 6 alkyl, —Ohalogen-substitutedC 1 -C 6 alkyl, —COOH, —COOC 1 -C 6 alkyl, —C 1 -C 6 alkylCOOC 1 -C 6 alkyl, —C 1 -C 6 alkylCOOH, —OC 1 -C 6 alkylCOOH, —CN, C 1 -C 6 alkylCN, NH 2 , NHC 1 -C 6 alkyl, N(C 1 -C 6 alkyl) 2 , —NHCOOC 1 -C 6 alkyl, C 1 -C 6 alkylCONH 2 , —CONH 2 , —CONHC 1 -C 6 alkyl, —NHCOC 1 -C 6 alkyl, —CON(C 1 -C 6 alkyl) 2 , —NHSO 2 C 1 -C 6 alkyl, SO 2 aryl, —SO 2 C 1 -C 6 alkyl, C 1 -C 6 alkyl SO 2 C 1 -C 6 alkyl, aryl, —NHCOaryl, and —NHCOheterocycle.
2. The compounds of claim 1 or pharmaceutically acceptable salts thereof wherein R 1 is substituted with 1 to 3 substituents selected from R 5 .
3. The compounds of claim 1 or pharmaceutically acceptable salts thereof wherein R 1 is C 1 -C 6 alkyl.
4. The compounds of claim 1 or pharmaceutically acceptable salts thereof wherein R 1 is benzyl.
5. The compounds of claim 1 or pharmaceutically acceptable salts thereof wherein R 2 is unsubstituted.
6. The compounds of claim 1 or pharmaceutically acceptable salts thereof wherein R 2 is hydrogen.
7. The compounds of claim 1 or pharmaceutically acceptable salts thereof wherein R 2 is C 1 -C 6 alkyl.
8. The compounds of claim 1 any one of claims 1 or pharmaceutically acceptable salts thereof wherein R 3 is hydrogen.
9. The compounds of claim 1 or pharmaceutically acceptable salts thereof wherein R 3 is C 1 -C 6 alkyl.
10. The compounds of claim 1 or pharmaceutically acceptable salts thereof wherein R 4 is hydrogen.
11. The compounds of claim 1 or pharmaceutically acceptable salts thereof wherein R 4 is C 1 -C 6 alkyl.
12. The compounds of claim 1 or pharmaceutically acceptable salts thereof wherein R 1 is selected from the group consisting of methyl, benzyl, 2-fluorobenzyl, 2-butenyl, 2-butynyl, 2-propenyl, benzyl, 2,5-difluorobenzyl, 2,4,5-trifluorobenzyl, 2-cyanobenzyl, 2-cyano-5-fluorobenzyl, 2-cyano-4,5-difluorobenzyl, 2,4-dichlorobenzyl, and 2,5-dichlorobenzyl, wherein the methyl, 2-butenyl and benzyl are unsubstituted or substituted with 1-3 substituents selected from R 5 .
13. The compounds of claim 1 or pharmaceutically acceptable salts thereof wherein R 2 is selected from the group consisting of 2-butynyl, 2-butenyl and benzyl, wherein the benzyl is unsubstituted or substituted with 1-3 substituents selected from the group R 5 .
14. The compounds of claim 1 or pharmaceutically acceptable salts thereof wherein R 5 is selected from the group consisting of trifluoromenthyl, halogen and —CN.
15. A compound or pharmaceutically acceptable salt, selected from the group consisting of:
16. A pharmaceutical composition which comprises a compound of claim 1 and a pharmaceutically acceptable carrier.
17. The pharmaceutical composition of claim 16 additionally comprising a second agent selected from the group consisting of metformin, pioglitazone, rosiglitazone, a sulfonylurea, and an HMG-CoA reductase inhibitor.
18. A method of treating a condition selected from the group consisting of insulin resistance, hyperglycemia, and Type 2 diabetes by administering a therapeutically effective amount of a compounds of claim 1 , or a pharmaceutically acceptable salt thereof to a patient in need thereof.